Targeting matrix metalloproteases to improve cutaneous wound healing.
Wound repair is a physiological event in which tissue injury initiates a repair process leading to restoration of structure and function of the tissue. Cutaneous wound repair can be divided into a series of overlapping phases including formation of fibrin clot, inflammatory response, granulation tissue formation incorporating re-epithelialisation and angiogenesis and finally, matrix formation and remodelling. Matrix metalloproteases (MMPs) are a family of neutral proteases that play a vital role throughout the entire wound healing process. They regulate inflammation, degrade the extracellular matrix (ECM) to facilitate the migration of cells and remodel the new ECM. However, excessive MMP activity contributes to the development of chronic wounds. Selective control of MMP activity may prove to be a valuable therapeutic approach to promote healing of chronic ulcers. Recent evidence indicates that the anticoagulant, activated protein C may be useful in the treatment of non-healing wounds by preventing excessive protease activity through inhibition of inflammation and selectively increasing MMP-2 activity to enhance angiogenesis and re-epithelialisation.
Xue
Meilang
M
Sutton Arthritis Research Laboratory Level 1, Royal North Shore Hospital, The University of Sydney, St Leonards, NSW, 2065, Australia.
Le
Nghia T V
NT
Jackson
Christopher J
CJ
D000818:Animals; D016503:Drug Delivery Systems / Q000379:methods*; D015971:Gene Expression Regulation, Enzymologic / Q000187:drug effects / Q000502:physiology; D006801:Humans; D061965:Matrix Metalloproteinase Inhibitors; D020782:Matrix Metalloproteinases / Q000096:biosynthesis* / Q000235:genetics; D011480:Protease Inhibitors / Q000627:therapeutic use*; D012867:Skin / Q000187:drug effects / Q000201:enzymology*; D014945:Wound Healing / Q000187:drug effects* / Q000235:genetics
D061965:Matrix Metalloproteinase Inhibitors; D011480:Protease Inhibitors; D020782:Matrix Metalloproteinases